Lab Genomics and Canexia Health have secured molecular diagnostic services (MolDX) coverage for Canexia Health's Follow It circulating tumor DNA (ctDNA) assay, which uses blood drawn from patients to analyze ctDNA in plasma.
The decision allows for Medicare coverage of Follow It for breast, lung, and colorectal cancers, the two firms said. Follow It can help guide cancer treatment, according to the companies.
